Mizuho lowered the firm’s price target on Harmony Biosciences to $28 from $54 and keeps a Buy rating on the shares ahead of the Q3 earnings report. The firm made across-the-board revisions and meaningfully lowered its near- and longer-term Wakix outlook. However, with 25% upside potential and the Zynerba deal not factored into its model, the firm maintains a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences price target lowered to $53 from $66 at Needham
- Harmony Biosciences price target lowered to $42 from $72 at Piper Sandler
- Harmony Biosciences announces topline results from the INTUNE study
- HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
- Harmony Biosciences completes acquisition of Zynerba